New research shows that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10–17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.
This article was originally published on MedicalXpress.com